Recently, BUBA Ventures, which has accelerated its investments in the fields of health, insurance, agriculture and digital communication, is preparing to break new ground in the world of science with its new investment.
Inanç Ortaç, CSO of Sarmal, which operates in the United States and recently signed an important cooperation with BUBA Ventures, said, “In order to prevent pandemics, we need to test almost everyone, regardless of their symptoms, and get test results immediately. The DeTaiL device we developed aims to achieve this. Our goal is to be able to test our temperature wherever we go, as if we were to measure our temperature, instead of closing in at home. But this test is more sensitive, specific, fast and low cost than all tests currently available, ”he said.
March 2021 Istanbul, Bringing together a wide investor network by supporting many initiatives, BUBA Ventures continues its investments in the field of health. Finally, BUBA Ventures, which has made an important cooperation with Sarmal operating in the United States, is signing a groundbreaking study for COVID 19.
As one of the most important biotech networks in California, Biocom, one of the two companies that emerged after Innovasion Labs, which was founded in 40, split into two in 10. He emphasized that Sarmal, who developed the technology in the field of DNA sequencing and genetics, started to actively invest after this division. Stating that their paths crossed with BUBA Ventures at this point, İnanç Ortaç noted that thanks to the investment of BUBA Ventures, they brought a very important project aimed at controlling the pandemic to the prototype stage in less than a year. İnanç Ortaç said that with the emergence of the pandemic, they noticed an important gap in testing methods and focused on developing a study that could control the pandemic.
"Our goal is to be able to test our temperature anywhere, anytime, instead of staying home."
Sarmal's CSO is İnanç Ortaç; “At the moment, all the methods we have are following the pandemic far behind. Among these methods, we can count all test methods, vaccines and treatment methods. In order to prevent our pandemic, we need to test almost everyone, regardless of their symptoms, every day and reach the test results immediately. The DeTaiL device we developed at Sarmal aims to achieve this. Our goal is to be tested as if we measure our temperature wherever we go, instead of staying home. But you cannot compromise the reliability of the test to achieve this. "This test we have developed is more sensitive, specific, fast and low cost than all tests currently available."
"The pandemic has taught us a lot"
Stating that new mutations for COVID 19 have also emerged, İnanç Ortaç said that the effect of vaccines and treatments against these mutations is discussed. Noting that the follow-up of this change in the virus is also very important, Ortaç continued his words as follows: “For this, again, a large-scale screening is required. At this point, another technology of Sarmal, "FLASH", comes into play. By detecting the genetic changes in the virus on a population scale, it enables the sequences to be searched by techniques such as DeTaiL and qPCR. Existing technologies are far from answering this. In this context, Sarmal develops key technologies necessary to control the current pandemic and to prevent such a pandemic from happening again. If DeTaiL and FLASH technologies were ready before this pandemic started, this pandemic could be taken under control before it spread to a few people. This pandemic has taught us many things. We now know better what must happen so that all this does not happen again. On this occasion, we have increased our activity in this direction and we are now trying to make it available in the near future ”.